TORONTO, June 14, 2021 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)
(Frankfurt: A2JMZC), a vertically
integrated medical cannabis leader with core operations in
Latin America and Europe, is pleased to announce the appointment
of Franziska Katterbach as President, Khiron Europe to replace
Tejinder Virk, who has resigned from
the Company.
Franziska Katterbach Appointed President of Khiron
Europe
Since her appointment in October 2019 to the role of Managing Director and
Chief Legal Counsel, Khiron Europe, Ms. Katterbach has been at the
forefront of Khiron's European operations. Franziska's promotion to
the position of President aligns with the Company's commitment to
diversity and inclusion throughout the organization, including at
the Executive level.
"I would like to congratulate Franziska on her appointment,
which comes at a very exciting time for our European team. Since
joining Khiron, Franziska has been a driving force behind our
European operations. Her regulatory expertise, strong leadership
skills and exceptional day-to-day management of operations have
allowed us to develop a differentiated, asset-light platform. Most
recently, the European team launched another new product into the
German market while more than tripling shipment volumes,
demonstrating strong execution in Europe's largest market," comments
Alvaro Torres, CEO and Director.
Franziska Katterbach, President, Khiron Europe, comments, "I am
a great believer in Europe's
medical cannabis market and am honoured to lead our world-class
team as we expand patient access, along with our market presence,
in Germany and the UK. On behalf
of the Company, I would like to thank Tejinder for his many
contributions to our European operations and wish him well in his
future endeavors."
Mr. Virk´s resignation will result in the forfeiture of 2.2
million stock options and 600,000 restricted share units previously
awarded.
About Khiron Life Sciences Corp.
Khiron is a leading
vertically integrated medical cannabis company with core operations
in Latin America and Europe. Leveraging wholly-owned medical health
centres and proprietary telemedicine platforms, Khiron combines a
patient-oriented approach, physician education programs, scientific
expertise, product innovation, and agricultural infrastructure to
drive prescriptions and brand loyalty with patients worldwide. The
Company has a sales presence in Colombia, Peru, Germany
and the UK, and is positioned to commence sales in Mexico and Brazil in 2021. The Company is led by
Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-provides-european-management-updates-301311923.html
SOURCE Khiron Life Sciences Corp.